APU
JAZZ icon

Alpine Partners USVI’s Jazz Pharmaceuticals JAZZ Stock Holding History

Alpine Partners USVI’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-7,168
Closed -$492K – 85
2013
Q2 		$492K Buy
+7,168
New +$438K 0.16% 89

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.44B AUM 28.5% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $28.2B AUM 21.78% 1-Year Est. Return

Alpine Partners USVI's JAZZ Position: Q3 2013 in Review

Alpine Partners USVI sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2013, closing a stake of 7,168 shares — an estimated $492K sold.

Alpine Partners USVI first reported a position in JAZZ in Q2 2013 and held it in 1 quarter. The position peaked at $492K in Q2 2013. 249 funds tracked by Wall St. Rank hold JAZZ as of Q3 2013.

  • Alpine Partners USVI reported no remaining Jazz Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Alpine Partners USVI sold 7,168 Jazz Pharmaceuticals shares in Q3 2013, an estimated $492K.
  • Alpine Partners USVI first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Alpine Partners USVI's Jazz Pharmaceuticals position peaked at $492K in Q2 2013.
  • 249 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2013.

Based on Alpine Partners USVI's 13F filing for Q3 2013, filed 14 Nov 2013.